SanjayJ.MathewMD

Professor; and Chair for Research in Psychiatry, Menninger Department of Psychiatry & Behavioral Sciences, Baylor College of Medicine. Staff Physician, Michael E. Debakey Veterans Affairs Medical Center.

Join to view full profile

Dr. Mathew is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. Mathew's full profile

Already have an account?

Office
1977 Butler Boulevard
Suite E4.189
Houston, TX 77030
Phone+1 713-798-5877
Is this information wrong?

Education & Training

New York Presbyterian Hospital (Columbia Campus)/New York State Psychiatric InstituteResidency, Psychiatry, 1997 - 2001
Baylor College of MedicineClass of 1997

Certifications & Licensure

TX State Medical License 2010 - 2025
NY State Medical License 1998 - 2025
American Board of Psychiatry and Neurology Psychiatry

Clinical Trials

Research Study for Major Depressive Disorder: Investigation of Glutamate Medications Start of enrollment: 2006 Dec 01
Completed
Phase 4
Staccato Alprazolam in Panic Attack Start of enrollment: 2007 May 01
Completed
Phase 2
Optimization of IV Ketamine for Treatment Resistant Depression Start of enrollment: 2008 Nov 01
Completed
Phase 2
Efficacy and Tolerability of Riluzole in Treatment Resistant Depression Start of enrollment: 2011 Jun 01
Completed
Phase 2
Fast-Fail Trials in Mood and Anxiety Spectrum Disorders; Kappa Opioid Receptor Phase 2a Start of enrollment: 2015 Jun 01
Completed
Phase 2
Study to Treat Major Depressive Disorder With a New Medication Start of enrollment: 2017 Sep 25
Completed
Phase 2
Ketamine in Veterans With Gulf War Illness Start of enrollment: 2021 Feb 01
Terminated
Early Phase 1
XEN1101 for Major Depressive Disorder Start of enrollment: 2021 Oct 19
Recruiting
Phase 2
Comparative Effectiveness of ECT vs. KETAMINE Over the Lifespan Start of enrollment: 2023 Oct 01
Enrolling by invitation
Phase 4
Roles: Principal Investigator, Contact
Join now to see all

Publications & Presentations

PubMed

1 citations
Neural connectivity moderators and mechanisms of ketamine treatment among treatment-resistant depressed patients: a randomized controlled trial.
Howland, R., Griffo, A., Panny, B., Price, R., Rengasamy, M., Mathew, S.> ;Ebiomedicine. 2024 Jan 1
Stereo-EEG-guided network modulation for psychiatric disorders: Surgical considerations.
Sheth, S., Shofty, B., Allawala, A., Xiao, J., Adkinson, J., Mathura, R., Pirtle, V., Myers, J., Oswalt, D., Provenza, N., Giridharan, N., Noecker, A., Banks, G., Gado...> ;Brain Stimulation. 2023 Dec 20
Anti-suicidal effects of IV ketamine in a real-world setting.
O'Brien, B., Lee, J., Kim, S., Tamman, A., Amarneh, D., Murphy, N., Averill, L., Nandra, G., Pannu, P., Swann, A., Jha, M., Mathew, S.> ;Psychiatry Research. 2024 Jan 1
1 citations
Choosing Between Ketamine and Electroconvulsive Therapy for Outpatients With Treatment-Resistant Depression-Advantage Ketamine?
Sanjay J Mathew, Manish K Jha, Amit Anand> ;JAMA Psychiatry. 2023 Dec 1
4 citations
Efficacy and safety of zuranolone co-initiated with an antidepressant in adults with major depressive disorder: results from the phase 3 CORAL study.
Sagar V Parikh, Scott T Aaronson, Sanjay J Mathew, Gustavo Alva, Charles DeBattista, Stephen Kanes, Robert Lasser, Amy Bullock, Mona Kotecha, JungAh Jung, Fiona Forres...> ;Neuropsychopharmacology. 2024 Jan 1
2 citations
NRX-101 (D-cycloserine plus lurasidone) vs. lurasidone for the maintenance of initial stabilization after ketamine in patients with severe bipolar depression with acut...
Andrew Nierenberg, Philip Lavin, Daniel C Javitt, Richard Shelton, Michael T Sapko, Sanjay Mathew, Robert E Besthof, Jonathan C Javitt> ;International Journal of Bipolar Disorders. 2023 Aug 13
Using latent profile analyses to classify subjects with anhedonia based on reward-related measures obtained in the FAST-MAS study.
Sabrina M Darrow, Diego A Pizzagalli, Moria Smoski, Sanjay J Mathew, John Nurnberger Jr, Sarah H Lisanby, Dan Iosifescu, James W Murrough, Hongqiu Yang, Richard D Wein...> ;Journal of Affective Disorders. 2023 Oct 15
1 citations
The why, when, where, how, and so what of so-called rapidly acting antidepressants.
Alan F Schatzberg, Sanjay J Mathew> ;Neuropsychopharmacology. 2024 Jan 1
Correction: Neural complexity EEG biomarkers of rapid and post-rapid ketamine effects in late-life treatment-resistant depression: a randomized control trial.
Nicholas Murphy, Amanda J F Tamman, Marijn Lijffijt, Dania Amarneh, Sidra Iqbal, Alan Swann, Lynnette A Averill, Brittany O'Brien, Sanjay J Mathew> ;Neuropsychopharmacology. 2023 Oct 1
Characterization of Extended-Release Lorazepam: Pharmacokinetic Results Across Phase 1 Clinical Studies.
Sanjay J Mathew, Shedly Jean-Lys, Rupinder Phull, Rama Yarasani> ;Journal of Clinical Psychopharmacology. 2023 Jun 19
1 citations
Pharmacotherapy for Treatment-Resistant Depression: Antidepressants and Atypical Antipsychotics.
Collin Vas, Ayush Jain, Mili Trivedi, Manish Kumar Jha, Sanjay J Mathew> ;The Psychiatric Clinics of North America. 2023 Jun 1
2 citations
Neural complexity EEG biomarkers of rapid and post-rapid ketamine effects in late-life treatment-resistant depression: a randomized control trial.
Nicholas Murphy, Amanda J F Tamman, Marijn Lijffijt, Dania Amarneh, Sidra Iqbal, Alan Swann, Lynnette A Averill, Brittany O'Brien, Sanjay J Mathew> ;Neuropsychopharmacology. 2023 Oct 1
16 citations
Pharmacotherapies for Treatment-Resistant Depression: How Antipsychotics Fit in the Rapidly Evolving Therapeutic Landscape.
Manish K Jha, Sanjay J Mathew> ;The American Journal of Psychiatry. 2023 Mar 1
5 citations
Replication of distinct trajectories of antidepressant response to intravenous ketamine.
Brittany O'Brien, Jaehoon Lee, Seungman Kim, Guriqbal S Nandra, Prabhneet Pannu, Alan C Swann, Nicholas Murphy, Amanda J F Tamman, Dania Amarneh, Marijn Lijffijt, Lynn...> ;Journal of Affective Disorders. 2023 Jan 15
Biomarkers in Psychiatric Drug Development: From Precision Medicine to Novel Therapeutics.
Rudy Lozano Carreon, Ana Maria Rivas-Grajales, Nicholas Murphy, Sanjay J Mathew, Manish K Jha> ;Advances in Neurobiology. 2023 Jan 1
Prefrontal network engagement by deep brain stimulation in limbic hubs.
Allawala, A., Bijanki, K., Oswalt, D., Mathura, R., Adkinson, J., Pirtle, V., Robinson, M., Harrison, M., Borton, D., Shofty, B., Mathew, S., Goodman, W., Pouratian, N...> ;Frontiers in Human Neuroscience. 2023 Jan 1
3 citations
Rapidity of Symptom Improvement With Intranasal Esketamine for Major Depressive Disorder: A Systematic Review and Meta-Analysis.
Rebecca S Hock, Anna Feeney, Nadia Iovieno, James W Murrough, Sanjay J Mathew, Dan V Iosifescu, Maurizio Fava, Manish K Jha, George I Papakostas> ;The Journal of Clinical Psychiatry. 2022 Dec 12
3 citations
Effect of Concomitant Benzodiazepines on the Antidepressant Effects of Ketamine: Findings From the RAPID Intravenous Ketamine Study.
Anna Feeney, Bettina B Hoeppner, Marlene P Freeman, Martina Flynn, Dan V Iosifescu, Madhukar H Trivedi, Gerard Sanacora, Sanjay J Mathew, Charles DeBattista, Dawn F Io...> ;The Journal of Clinical Psychiatry. 2022 Nov 14
25 citations
A Novel, Brief, Fully Automated Intervention to Extend the Antidepressant Effect of a Single Ketamine Infusion: A Randomized Clinical Trial.
Rebecca B Price, Crystal Spotts, Benjamin Panny, Angela Griffo, Michelle Degutis, Nicolas Cruz, Elizabeth Bell, Kevin Do-Nguyen, Meredith L Wallace, Sanjay J Mathew, R...> ;The American Journal of Psychiatry. 2022 Dec 1
23 citations
International pooled patient-level meta-analysis of ketamine infusion for depression: In search of clinical moderators.
Rebecca B Price, Nicholas Kissel, Andrew Baumeister, Rebecca Rohac, Mary L Woody, Elizabeth D Ballard, Carlos A Zarate Jr, William Deakin, Chadi G Abdallah, Adriana Fe...> ;Molecular Psychiatry. 2022 Dec 1
4 citations
A Participant-Level Integrative Data Analysis of Differential Placebo Response for Suicidal Ideation and Nonsuicidal Depressive Symptoms in Clinical Trials of Intraven...
Bartholt Bloomfield-Clagett, Elizabeth D Ballard, Deanna K Greenstein, Samuel T Wilkinson, Michael F Grunebaum, James W Murrough, Sanjay J Mathew, Jennifer L Phillips,...> ;The International Journal of Neuropsychopharmacology. 2022 Oct 25
14 citations
An Update on Community Ketamine Practices.
Brittany O'Brien, Samuel T Wilkinson, Sanjay J Mathew> ;The American Journal of Psychiatry. 2022 May 1
2 citations
A Novel Approach to Link Genetics and Human MRI Identifies AKAP7-Dependent Subicular/Prefrontal Functional Connectivity as Altered in Suicidality.
Guillermo Poblete, Tien Nguyen, Savannah Gosnell, Olutayo Sofela, Michelle Patriquin, Sanjay J Mathew, Alan Swann, David A Nielsen, Thomas R Kosten, Ramiro Salas> ;Chronic Stress. 2022 Mar 21
2 citations
Nighttime Sleep Quality and Daytime Sleepiness Predicts Suicide Risk in Adults Admitted to an Inpatient Psychiatric Hospital.
Christopher A Shepard, Katrina A Rufino, Jaehoon Lee, Tiffany Tran, Kieran Paddock, Chester Wu, John M Oldham, Sanjay J Mathew, Michelle A Patriquin> ;Behavioral Sleep Medicine. 2022 Mar 17
A comparison of the safety, feasibility, and tolerability of ECT and ketamine for treatment-resistant depression.
Amanda Tamman, Amit Anand, Sanjay J Mathew> ;Expert Opinion on Drug Safety. 2022 Jun 1
Join now to see all

Journal Articles

Double-Blind, Placebo-Controlled, Dose-Ranging Trial of Intravenous Ketamine as Adjunctive Therapy in Treatment-Resistant Depression (TRD)
Sanjay J Mathew, Madhukar H Trivedi, Lee C Chang, Dan V Iosifescu, Manish K Jha, Maurizio Fava, Marlene P Freeman, Cristina Cusin, James Murrough, George I Papakostas,..., Nature
Endogenous Opioid System Dysregulation in Depression: Implications for New Therapeutic Approaches
Sanjay Mathew, Jordan F Karp, Nature

Authored Content

F179. Epigenetic Biomarkers in Women with Posttraumatic Stress Disorder After CRF1 Receptor Antagonist TreatmentApril 2018
F179. Epigenetic Biomarkers in Women with Posttraumatic Stress Disorder After CRF1 Receptor Antagonist TreatmentApril 2018

Press Mentions

Researchers Discover Positive Effects of Intravenous Ketamine for Treatment-Resistant DepressionMay 25th, 2023
Treatment for Anxiety: Medications and OptionsApril 6th, 2023
2022 Leading Research AchievementsJanuary 5th, 2023
Join now to see all

Grant Support

Optimization Of IV Ketamine For Treatment Resistant Major DepressionNational Institute Of Mental Health2010–2012
2/3-Efficacy And Tolerability Of Riluzole In Treatment-Resistant DepressionNational Institute Of Mental Health2010–2012
Optimization Of IV Ketamine For Treatment Resistant Major DepressionNational Institute Of Mental Health2009
Optimization Of IV Ketamine For Treatment Resistant Major DepressionNational Center For Research Resources2009
Continuation Riluzole In Prevention Of Relapse Following Ketamine In DepressionNational Center For Research Resources2007–2009
MRS Neurometabolites In Chronic Fatigue Syndrome, GAD And Healthy VolunteersNational Center For Research Resources2008
Proton MRS Studies In Generalized Anxiety DisorderNational Institute Of Mental Health2004–2008
MRS Neurometabolites In Chronic Fatigue Syndrome, GAD, And Healthy VolunteersNational Center For Research Resources2007
Adenocine Receptor Polymorphisms And Physiologic Response To Caffeine In PDNational Center For Research Resources2006
MRS Neurometabolites In Chronic Fatigue Syndrome, Generalized Anxiety DisorderNational Center For Research Resources2005–2006